Drug Profile


Alternative Names: Ara-C asparagine conjugate; Asparagine ara-C conjugate; Asparagine cytarabine conjugate; Astarabine; BSR-236; Cytarabine asparagine conjugate

Latest Information Update: 21 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioSight
  • Class Amino acids; Antineoplastics; Arabinonucleosides; Drug conjugates; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Preclinical Chronic myeloid leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 14 Dec 2017 Updated adverse events and efficacy data from a phase I/II trial in Acute myeloid leukaemia and Acute lymphocytic leukaemia presented at the 59th Annual Meeting and Exposition of the American Society of Haematology (ASH-2017)
  • 20 Sep 2017 BioSight completes a phase I/II trial for Acute myeloid leukaemia and Acute lymphoblastic leukaemia in Israel (NCT02544438)
  • 09 Aug 2017 BioSight completes enrolment in its phase I/II trial for Acute myeloid leukaemia and Acute lymphoblastic leukaemia in Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top